Unknown

Dataset Information

0

Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.

ABSTRACT:

SUBMITTER: Wang Q 

PROVIDER: S-EPMC9847504 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.

Wang Qian Q   Bowen Anthony A   Valdez Riccardo R   Gherasim Carmen C   Gordon Aubree A   Liu Lihong L   Ho David D DD  

The New England journal of medicine 20230111 6

Similar Datasets

Unknown Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
| S-EPMC10101054 | biostudies-literature
Unknown Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5.
| S-EPMC9552143 | biostudies-literature
Unknown A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
| S-EPMC11093671 | biostudies-literature
Unknown Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
| S-EPMC9933930 | biostudies-literature
Unknown Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants.
| S-EPMC10403593 | biostudies-literature
Unknown COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2.
| S-EPMC10537670 | biostudies-literature
Unknown Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
| S-EPMC10157119 | biostudies-literature
Unknown Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5-adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients.
| S-EPMC10513127 | biostudies-literature
Unknown Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study.
| S-EPMC11359987 | biostudies-literature
Unknown Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
| S-EPMC10447540 | biostudies-literature